长亮科技：10月24日召开董事会会议

Group 1 - The core point of the article is that Changliang Technology (SZ 300348) held its 30th meeting of the 5th Board of Directors on October 24, 2025, to review the proposal regarding the company's Q3 2025 report [1] - For the first half of 2025, the revenue composition of Changliang Technology is as follows: software development business accounted for 92.07%, maintenance service business accounted for 5.97%, integration accounted for 1.95%, and other businesses accounted for 0.01% [1] - As of the time of reporting, the market capitalization of Changliang Technology is 11.7 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market is facing fundraising difficulties [1]